Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Pazopanib recommended for kidney cancer

  • Comment

The National Institute for Health and Clinical Excellence has approved a new treatment for kidney cancer.

NICE has recommended Pazopanib as a first-line treatment for those with advanced kidney cancer in certain circumstances.

It has also been recommended for patients who have not previously had cytokine therapy and either remain active or only struggle with strenuous activity.

GlaxoSmithKline, which manufactures the drug, has agreed a discount on the list price with a possible future rebate linked to the outcome of a clinical trial.

Broadcaster James Whale, founder and chairman of the James Whale Fund for Kidney Cancer and a kidney cancer survivor, said: “Kidney cancer patients will find this approval of the cancer drug Pazopanib a great comfort.

“NICE has been fully aware that the mood of the government and the general public is that terminally ill cancer patients should not be denied cancer treatment and, after the farce surrounding the refusal of Everolimus earlier last year, some good news is long overdue.

“As someone who has been directly affected by kidney cancer, I understand just how imperative access to these life-prolonging drugs is.”

We’re going viral! Have you friends heard about the ‘seat on the board’ petition? Let’s ensure nurses are actively involved in the new commissioning consortia.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.